prostate cancer

[Biosplice Therapeutics, Inc.] Biosplice Therapeutics, Inc. announced the dosing of the first subject in a Phase Ib, open-label, multicenter, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with advanced solid tumors.

[Scientific Reports] Quantitative glycoprotein profiling identified androgen-regulated glycoprotein networks associated with supraphysiologic androgen-mediated inhibition of prostate cancer cell proliferation, and androgen-regulated glycoproteins in clinical prostate tissues.

[Scientific Reports] Cabazitaxel (CBZ) was approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). Researchers explored the optimal treatment for CRPC in the post-cabazitaxel setting using PC3 (CBZ-sensitive) and PC3CR cells (CBZ-resistant).

[Nature Communications] Scientists identified G3BP1 as an interactor of SPOP and functions as a competitive inhibitor of Cul3SPOP, suggesting a distinctive mode of Cul3SPOP inactivation in prostate cancer.

[Cancer Gene Therapy] Investigators uncovered that the transcription factor p53 could upregulate miR-519d-3p expression to directly suppress the expression of E2F transcription factor 1 (E2F1), thus inhibiting prostate cancer growth and metastasis.

[Bioengineered] The authors investigated the function and mechanism of demethyltransferase fat mass and obesity-associated protein (FTO) in prostate cancer (PCa). FTO regulated the proliferation, migration and invasion of PCa via regulating the expression level of MC4R.